Previous 10 | Next 10 |
2024-01-03 07:15:08 ET More on Dyne Therapeutics Seeking Alpha’s Quant Rating on Dyne Therapeutics Historical earnings data for Dyne Therapeutics Financial information for Dyne Therapeutics For further details see: Dyne surges on positive Phase 1/2...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 8, 2024 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Follo...
2023-12-29 17:15:31 ET More on bluebird bio, CRISPR Therapeutics, etc. bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why M...
2023-12-28 10:07:00 ET Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on the market but no profits to speak of, it's a bit of an oddit...
2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...
2023-12-22 10:15:00 ET Could the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a towering, innovative, and profitable growth business, as biopharma Vertex Pharmaceuticals (NASDAQ: VRTX) is today? It's more likely than it might seem at first ...
2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...
2023-12-17 09:45:00 ET The word "revolutionary" sometimes gets thrown around a lot, but it certainly applies to Sarepta Therapeutics (NASDAQ: SRPT) . This midcap biotech company has developed several treatments for Duchenne muscular dystrophy (DMD) -- even earning approval for the f...
2023-12-13 14:40:30 ET Citi started coverage of Sarepta Therapeutics ( NASDAQ: SRPT ) with a buy rating, stating that it likes the risk/reward heading into the FDA’s review of the company’s drug Elevidys for full approval for the treatment of Duchenne muscular dystroph...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 08:00:00 ET On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy (DMD), Elevidys, from an accelerated approval to a full appro...
2024-07-04 06:35:00 ET When a company obtains positive news from the Food and Drug Administration (FDA), such as the approval of a treatment or a label expansion, it can mark a milestone for the business and lead to significant revenue growth. The risk with many biotech stocks is not knowin...